Replies to post #547626 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

That’s an interesting question regarding primary tumor as opposed to the recurrent. I am certainly not qualified to explain it because the treatment protocols are different for the PD1 study and the P3 obviously did not include the same agents.

Anyone can see that there is clearly significant evidence of efficacy for all three groups.

However, the efficacy for “Adi ATL-DC + PD-1 mAb” is amazing and it will be a fascinating data set to analyze when it’s more complete!

[TopherTink]

It could be related to patient selection factors being different, and remember r the n # in a phase one is quite small.

[exwannabe]

On the combo trial it is not clear from LL's slide but PD1 is use concurrent with DC on both arms.

The patients that received neo PD1 + DC + PD1 did substantially worse than patients who received DC + PD1 (w/o the neo PD1). That would be very odd.

Given the P value here is around .37 (the K/M chart can be read point by point and P calculated) one might come to the reasonable conclusion that the difference is just random chance. And if so, the results really mean nothing at this stage.